AI Summary & Key Takeaways
AI InsightTherefore, it should be considered in patients with back pain, anemia, and kidney failure, and treatment delay should be avoided.
📌 3 Key Takeaways
Abstract
Multiple myeloma is a malignant disease that can result in organ damage due to abnormal plasma cell growth and immunoglobulin or light chain overproduction in the bone marrow. It is the second most common hematologic cancer after lymphomas. Approximately half of the patients have kidney failure. Bone involvement is one of the most common organ damage in myeloma. Bone involvement is a feature that has diagnostic and prognostic value, shows tumor burden, organ damage, and affects the patient's quality of life. With the recent advances in Multiple Myeloma treatment, the survival of patients has increased dramatically. Although new agents contribute positively to total survival and disease-free life span, they cannot prevent disease recurrence. Therefore, it should be considered in patients with back pain, anemia, and kidney failure, and treatment delay should be avoided.